-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Ruibo Bio-B (06938.HK) announced that it has submitted a phase I clinical trial application for the company's siRNA product RBD3133 injection targeting INHBE in the European Union to treat overweight and obesity.

Zhitongcaijing·10/07/2026 22:49:07
Listen to the news
Zhitong Finance App News, Ruibo Bio-B (06938.HK) announced that it has submitted a phase I clinical trial application for the company's siRNA product RBD3133 injection targeting INHBE in the European Union to treat overweight and obesity.